Zscaler (ZS) Gets a Buy Rating from Credit Suisse

Credit Suisse analyst Yaoxian Chew maintained a Buy rating on Zscaler (ZS – Research Report) on May 27 and set a price target of $310.00. The company’s shares closed last Friday at $160.00, close to its 52-week low of $125.12.

Chew has an average return of 6.6% when recommending Zscaler.

According to TipRanks.com, Chew is ranked #4160 out of 7945 analysts.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Zscaler with a $216.25 average price target, implying a 38.2% upside from current levels. In a report issued on May 27, BMO Capital also maintained a Buy rating on the stock with a $172.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Based on Zscaler’s latest earnings release for the quarter ending January 31, the company reported a quarterly revenue of $256 million and GAAP net loss of $100 million. In comparison, last year the company earned revenue of $157 million and had a GAAP net loss of $67.54 million.

Based on the recent corporate insider activity of 80 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ZS in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Zscaler, Inc., formerly known as SafeChannel Inc., is a cloud-based security solutions provider. The company offers a full range of enterprise network security solutions including internet security, web security, vulnerability management, firewalls, antivirus, and control over user activity in mobile, cloud computing, and Internet of Things environments.

Read More on ZS:

• Trainline (TNLIF) Receives a Hold from J.P. Morgan
• Analysts Are Bullish on These Healthcare Stocks: Tempest Therapeutics (TPST), Spectrum Pharmaceuticals (SPPI)
• Weekly Market Review: Market Gains Ahead of Holiday
• RBC Capital Reaffirms Their Hold Rating on Summit Midstream (SMLP)
• RBC Capital Maintains a Hold Rating on NextGen Healthcare (NXGN)